TCRX - NASDAQ
TScan Therapeutics, Inc.
$0.97
+0.14%TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotTScan Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
TScan Therapeutics, Inc. Income Statement
TCRX • NASDAQ
| TScan Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
10.3M | 2.8M | 21M | 13.5M | 10.1M | 1.1M | 0.0 | |
GROSS PROFIT | |||||||
(2.9M) | (0.0) | (0.0) | (0.0) | (0.0) | (20.6M) | (519K) | |
7.5M | 2.8M | 21M | 13.5M | 10.1M | -19.5M | -519K | |
OPERATING INCOME | |||||||
(143.3M) | (137.6M) | (114.5M) | (80.2M) | (58.8M) | (6.7M) | (14.2M) | |
(32M) | (29.6M) | (25.5M) | (20.4M) | (13.8M) | (6.7M) | (4.8M) | |
(114.2M) | (107.4M) | (88.2M) | (59.8M) | (45M) | (20.6M) | (9.4M) | |
-135.8M | -134.8M | -93.5M | -66.6M | -48.6M | -26.2M | -14.2M | |
PRE-TAX INCOME | |||||||
(2.8M) | (3.7M) | (3.8M) | (1.2M) | (0.0) | (0.0) | (0.0) | |
6M | 8.4M | 4.2M | 415K | 16K | 106K | 0.0 | |
-2.9M | (728K) | (862K) | (0.0) | (0.0) | -20.6M | (0.0) | |
6M | 7.3M | 4.2M | 415K | 16K | 106K | 552K | |
-129.8M | -127.5M | -89.2M | -66.2M | -48.6M | -26.1M | -13.7M | |
NET INCOME | |||||||
-129.8M | -127.5M | -89.2M | -66.2M | -48.6M | -26.1M | -13.1M |
SEC Filings
TCRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 17, 2026 | May 20, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 02, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 26, 2025 | November 25, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your TCRX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.